Merdad Parsey - 27 Nov 2024 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)

Role
Chief Medical Officer
Signature
/s/ Amy Kim by Power of Attorney for Merdad Parsey
Issuer symbol
GILD
Transactions as of
27 Nov 2024
Net transactions value
-$6,014,325
Form type
4
Filing time
29 Nov 2024, 20:10:23 UTC
Previous filing
07 Nov 2024
Next filing
11 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GILD Common Stock Options Exercise $3,318,468 +57,294 +58% $57.92 156,893 27 Nov 2024 Direct
transaction GILD Common Stock Options Exercise $5,761,220 +88,119 +56% $65.38 245,012 27 Nov 2024 Direct
transaction GILD Common Stock Sale $5,259,297 -57,294 -23% $91.79 187,718 27 Nov 2024 Direct F1
transaction GILD Common Stock Sale $8,106,948 -88,119 -47% $92.00 99,599 27 Nov 2024 Direct
transaction GILD Common Stock Sale $477,381 -5,200 -5.2% $91.80 94,399 27 Nov 2024 Direct F2
transaction GILD Common Stock Sale $293,679 -3,199 -3.4% $91.80 91,200 27 Nov 2024 Direct F3
transaction GILD Common Stock Sale $956,708 -10,399 -11% $92.00 80,801 27 Nov 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GILD Non-qualified Stock Option (Right to Buy) Options Exercise $0 -57,294 -47% $0.000000 64,376 27 Nov 2024 Common Stock 57,294 $57.92 Direct F4
transaction GILD Non-qualified Stock Option (Right to Buy) Options Exercise $0 -88,119 -100% $0.000000 196 27 Nov 2024 Common Stock 88,119 $65.38 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale prices reported for the transactions reported here range from $91.451 to $92.095. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F2 Sale prices reported for the transactions reported here range from $91.458 to $92.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F3 Sale prices reported for the transactions reported here range from $91.451 to $92.035. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F4 The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.